1 / 1
bictegravir/emtricitabine/tenofovir alafenamide(Biktarvy)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Gilead
Formulation:
TABLET
Validity period:
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Xagrid(bictegravir/emtricitabine/tenofovir alafenamide) Instructions:Uses,Dosage, Side Effects
BIKTARVY contains three active components: bictegravir, which is an integrase strand transfer inhibitor (INSTI); emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI); and tenofovir alafenamide (TAF), another NRTI. It is formulated as an oral tablet and serves as a complete regimen, meaning it does not require additional antiretroviral agents.
The medication is designed to suppress HIV-1 replication and is available in different strengths to accommodate various patient weights, starting from 14 kg. It was initially approved in the U.S. in 2018 and is intended for long-term management of HIV-1, helping to reduce viral load and support immune function.
